Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Роль лучевой терапии в лечении болезни Розаи–Дорфмана: обзор литературы и клиническое наблюдение пациента с изолированным поражением кожи
Роль лучевой терапии в лечении болезни Розаи–Дорфмана: обзор литературы и клиническое наблюдение пациента с изолированным поражением кожи
Потапенко В.Г., Белоусова И.Э., Виноградова Ю.Н. и др. Роль лучевой терапии в лечении болезни Розаи–Дорфмана: обзор литературы и клиническое наблюдение пациента с изолированным поражением кожи. Современная Онкология. 2020; 22 (4): 120–124. DOI: 10.26442/18151434.2020.4.200480
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Болезнь Розаи–Дорфмана (БРД) – редкий вариант нелангергансоклеточного гистиоцитоза. Широкий спектр проявлений, наличие системной и изолированной кожной форм, малое количество описаний обусловливают трудности диагностики.
Цель. Обзор литературы и описание пациента с кожной формой БРД.
Результаты. У мужчины 56 лет в левой височной области в октябре 2019 г. появилось опухолевидное образование. После радикального удаления в течение 2 нед отмечен повторный рост в зоне операции. По результатам гистологического и иммуногистохимического исследований с последующим стадированием верифицирована кожная форма БРД с изолированным поражением кожи лица и височной области. Проведено облучение в суммарной дозе 36 Гр. Получена положительная динамика в виде уменьшения образования. В течение 4 мес ответ сохраняется.
Заключение. Лучевая терапия у пациента с локализованной формой БРД привела к длительному противоопухолевому ответу.
Ключевые слова: болезнь Розаи–Дорфмана, облучение, гистиоцитоз, эмпериополез.
Aim. Literature review and presentation of the patient with cutaneous form of RDD.
Results. The patient is a 56 y.o male. In October 2019 he noticed a tumour in the left temporal area. After 3 weeks the tumor was removed. During the next two weeks the tumour recurred within the post-operative scar. After the review of the specimen and staging the skin form Rosai–Dorfman disease was diagnosed. Irradiation (total dose 36 Gr) was conducted. The tumor lessened. Through the next 4 months response is stable.
Сonclusion. Radiation therapy as a second line of treatment of the skin RDD led to a stable response.
Key words: Rosai–Dorfman disease, irradiation, histiocytosis, emperiopolesis.
Цель. Обзор литературы и описание пациента с кожной формой БРД.
Результаты. У мужчины 56 лет в левой височной области в октябре 2019 г. появилось опухолевидное образование. После радикального удаления в течение 2 нед отмечен повторный рост в зоне операции. По результатам гистологического и иммуногистохимического исследований с последующим стадированием верифицирована кожная форма БРД с изолированным поражением кожи лица и височной области. Проведено облучение в суммарной дозе 36 Гр. Получена положительная динамика в виде уменьшения образования. В течение 4 мес ответ сохраняется.
Заключение. Лучевая терапия у пациента с локализованной формой БРД привела к длительному противоопухолевому ответу.
Ключевые слова: болезнь Розаи–Дорфмана, облучение, гистиоцитоз, эмпериополез.
________________________________________________
Aim. Literature review and presentation of the patient with cutaneous form of RDD.
Results. The patient is a 56 y.o male. In October 2019 he noticed a tumour in the left temporal area. After 3 weeks the tumor was removed. During the next two weeks the tumour recurred within the post-operative scar. After the review of the specimen and staging the skin form Rosai–Dorfman disease was diagnosed. Irradiation (total dose 36 Gr) was conducted. The tumor lessened. Through the next 4 months response is stable.
Сonclusion. Radiation therapy as a second line of treatment of the skin RDD led to a stable response.
Key words: Rosai–Dorfman disease, irradiation, histiocytosis, emperiopolesis.
Полный текст
Список литературы
1. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 1969; 87 (1): 63–70.
2. Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127 (22): 2672–81. DOI: 10.1182/blood-2016-01-690636
3. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 1990; 7 (1): 19–73.
4. Должанский О.В., Пальцева Е.М., Морозова М.М. и др. Солитарная эпителиоидная гемангиоэндотелиома в сочетании с нодулярным паренхиматозным амилоидозом легкого и болезнью Розаи–Дорфмана. Архив патологии. 2018; 80 (2): 52–9.
[Dolzhanskiy O.V., Pal'tseva Ye.M., Morozova M.M. et al. Solitary epithelioid hemangioendothelioma in combination with nodular parenchymal amyloidosis of the lung and Rosai–Dorfman's disease. Archiv of Patology. 2018; 80 (2): 52–9 (In Russ).]
5. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120 (13): 2700–3.
6. Chakraborty R, Hampton OA, Shen X et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124 (19): 3007–15.
7. Pulsoni A, Anghel G, Falcucci P et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): report of a case and literature review. Am J Hematol 2002; 69 (1): 67–71.
8. Abla O, Jacobsen E, Picarsic J et al. Consensus recommendations for the diagnosis and clinical management of Rosai–Dorfman–Destombes disease. Blood 2018; 131 (26): 2877–90.
9. Меликян А.Л. Синусный гистиоцитоз с массивной лимфаденопатией (болезнь Розаи–Дорфмана). Обзор литературы и случай из практики. Клин. онкогематология. 2008; 1 (3): 252–8.
[Melikyan A.L. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). Literature review and case from practice. Clin Oncohematol. 2008; 1 (3): 252–8 (In Russian).]
10. Sathyanarayanan V, Issa A, Pinto R et al. Rosai–Dorfman disease: the MD Anderson cancer center experience. Clin Lymphoma Myeloma Leuk 2019; 19 (11): 709–14.
11. Al-Khateeb TH. Cutaneous Rosai–Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg. 2016; 74 (3): 528–40.
12. Ян C., Гветадзе Ш.Р., Илькаев К.Д. и др. Экстранодальная интраоссальная болезнь Розаи–Дорфмана в области нижней челюсти: описание клинического случая и обзор литературы. Опухоли головы и шеи. 2018; 8 (2): 34–8. DOI: 10.17650/2222-1468-2018-8-2-34-38
[Yan C., Gvetadze S.R., Il'kayev K.D. et al. Extranodal intraosseous Rozai–Dorfman disease in the mandible: a description of a clinical case and a review of the literature. Head and Nick Tumors. 2018; 8 (2): 34–8. DOI: 10.17650/2222-1468-2018-8-2-34-38 (in Russian).]
13. Goyal G, Ravindran A, Young JR et al. Clinicopathological features, treatment approaches, and outcomes in Rosai–Dorfman disease. Haematologica 2020; 105 (2): 348–57. DOI: 10.3324/haematol.2019.219626
14. Kutlubay Z, Bairamov O, Sevim A et al. Rosai–Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol 2014; 36 (4): 353–7. DOI: 10.1097/DAD.0b013e31829e5564
15. James WD, Berger T, Elston D. Cutaneous lymphoid hyperplasia, cutaneous T-cell lymphoma, other malignant lymphomas, and allied diseases. Andrews' Diseases of the Skin, Clinical Dermatology. 9th ed. Philadelphia: WB Saunders Company, 2019; p. 918–42.
16. Picarsic J, Jaffe R. Pathology of histiocytic neoplasms and related disorders. In: Abla O, Janka G. Histiocytic Disorders. Zurich, Switzerland: Springer International Publishing, 2018; p. 3–50.
17. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 2014; 124 (4): 483–92.
18. Ковригина А.М. Морфологическая характеристика реактивных изменений лимфоузлов. Клин. онкогематология. 2009; 2 (4): 297–305.
[Kovrigina A.M. Morphological characteristics of lymph node reactive changes. Clin Oncohematol. 2009; 2 (4): 297–305 (in Russian).]
19. Швец О.А., Абрамов Д.С., Хорева А.Л. и др. Лимфаденопатия по типу болезни Розаи–Дорфмана у пациента с синдромом Вискотта–Олдрича: сложности диагностики. Вопр. гематологии/онкологии и иммунопатологии в педиатрии. 2020; 19 (1): 108–15.
[Shvets O.A., Abramov D.S., Khoreva A.L. et al. Rosay–Dorfman – like lymphadenopathy in a patient with Wiskott–Aldrich syndrome: diagnostic difficulties. Pediatric Hematology/Oncology and Immunopathology. 2020; 19 (1): 108–15 (in Russian).]
20. Потапенко В.Г., Леенман Е.Е., Потихонова Н.А. и др. Лихорадка, ассоциированная с металлоконструкцией. Клиническое наблюдение. Журн. инфектологии. 2019; 12 (3): 126–9. DOI: 10.22625/2072-6732-2019-11-3-126-130
[Potapenko V.G., Leyenman Ye.Ye., Potikhonova N.A. et al. Fever associated with hardware. Clinical observation. J Infectol. 2019; 12 (3): 126–9. DOI: 10.22625/2072-6732-2019-11-3-126-130 (in Russian).]
21. Vaamonde R, Cabrera JM, Vaamonde-Martin RJ et al. Silicone granulomatous lymphadenopathy and siliconomas of the breast. Histol Histopathol 1997; 12: 1003–11.
22. Knösel T, Meisel H, Borgmann A et al. Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol 2005; 58 (8): 872–5. DOI: 10.1136/jcp.2004.022756
23. Соколовский Е.В., Михеев Г.Н., Рыбакова М.Г. и др. Синусный гистиоцитоз кожи лица нелангергансового типа (кожная форма болезни Розаи–Дорфмана). Вестн. дерматологии и венерологии. 2018; 94 (5): 66–71. DOI: 10.25208/0042-4609-2018-94-5-66-71
[Sokolovskiy Ye.V., Mikheyev G.N., Rybakova M.G. et al. Sinus histiocytosis of the skin of the face of the nonlangerganic type (cutaneous form of Rosai–Dorfman disease). Vestnik dermatologii i venerologii. 2018; 94 (5): 66–71. DOI: 10.25208/0042-4609-2018-94-5-66-71 (In Russian).]
24. Jordan MB, Hult A, Filipovich A. Histiocytic Disorders. In: Hematology: Basic Principles and Practice. Elsevier Inc., 2018.
25. Потекаев Н.Н., Львов А.Н., Бобко С.И. и др. Кожная форма болезни Розаи–Дорфмана. Клин. дерматология и венерология. 2017; 16 (1): 30–9. DOI: 10.17116/klinderma201716130-38
[Potekayev N.N., Lvov A.N., Bobko S.I. et al. Cutaneous form of Rosai–Dorfman disease. Rus J Clin Dermatol Venerol. 2017; 16 (1): 30–9. DOI: 10.17116/klinderma201716130-38 (In Russian).]
26. Chen HH, Zhou SH, Wang SQ et al. Factors associated with recurrence and therapeutic strategies for sinonasal Rosai–Dorfman disease. Head Neck 2011; 34 (10): 1504–13. DOI: 10.1002/hed.21832
27. Ferry JA, Klepeis V, Sohani AR et al. IgG4-related Orbital Disease and Its Mimics in a Western Population. Am J Surg Pathol 2015; 39 (12): 1688–700. DOI: 10.1097/PAS.0000000000000497
28. Tsang WY, Chan JK, Ho WK et al. Extranodal Rosai–Dorfman disease: an uncommon cause of persistent nodule in the ear. J Laryngol Otol 1992; 106 (3): 249–51. DOI: 10.1017/s0022215100119188
29. Andriko JA, Morrison A, Colegial CH et al. Rosai–Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol 2001; 14 (3): 172–8. DOI: 10.1038/modpathol.3880278
30. Forest F, N'guyen AT, Fesselet J et al. Meningeal Rosai–Dorfman disease mimicking meningioma. Ann Hematol 2014; 93 (6): 937–40. DOI: 10.1007/s00277-013-1994-8
2. Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127 (22): 2672–81. DOI: 10.1182/blood-2016-01-690636
3. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 1990; 7 (1): 19–73.
4. Dolzhanskiy O.V., Pal'tseva Ye.M., Morozova M.M. et al. Solitary epithelioid hemangioendothelioma in combination with nodular parenchymal amyloidosis of the lung and Rosai–Dorfman's disease. Archiv of Patology. 2018; 80 (2): 52–9 (In Russ).
5. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120 (13): 2700–3.
6. Chakraborty R, Hampton OA, Shen X et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124 (19): 3007–15.
7. Pulsoni A, Anghel G, Falcucci P et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): report of a case and literature review. Am J Hematol 2002; 69 (1): 67–71.
8. Abla O, Jacobsen E, Picarsic J et al. Consensus recommendations for the diagnosis and clinical management of Rosai–Dorfman–Destombes disease. Blood 2018; 131 (26): 2877–90.
9. Melikyan A.L. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). Literature review and case from practice. Clin Oncohematol. 2008; 1 (3): 252–8 (In Russian).
10. Sathyanarayanan V, Issa A, Pinto R et al. Rosai–Dorfman disease: the MD Anderson cancer center experience. Clin Lymphoma Myeloma Leuk 2019; 19 (11): 709–14.
11. Al-Khateeb TH. Cutaneous Rosai–Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg. 2016; 74 (3): 528–40.
12. Yan C., Gvetadze S.R., Il'kayev K.D. et al. Extranodal intraosseous Rozai–Dorfman disease in the mandible: a description of a clinical case and a review of the literature. Head and Nick Tumors. 2018; 8 (2): 34–8. DOI: 10.17650/2222-1468-2018-8-2-34-38 (in Russian).
13. Goyal G, Ravindran A, Young JR et al. Clinicopathological features, treatment approaches, and outcomes in Rosai–Dorfman disease. Haematologica 2020; 105 (2): 348–57. DOI: 10.3324/haematol.2019.219626
14. Kutlubay Z, Bairamov O, Sevim A et al. Rosai–Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol 2014; 36 (4): 353–7. DOI: 10.1097/DAD.0b013e31829e5564
15. James WD, Berger T, Elston D. Cutaneous lymphoid hyperplasia, cutaneous T-cell lymphoma, other malignant lymphomas, and allied diseases. Andrews' Diseases of the Skin, Clinical Dermatology. 9th ed. Philadelphia: WB Saunders Company, 2019; p. 918–42.
16. Picarsic J, Jaffe R. Pathology of histiocytic neoplasms and related disorders. In: Abla O, Janka G. Histiocytic Disorders. Zurich, Switzerland: Springer International Publishing, 2018; p. 3–50.
17. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 2014; 124 (4): 483–92.
18. Kovrigina A.M. Morphological characteristics of lymph node reactive changes. Clin Oncohematol. 2009; 2 (4): 297–305 (in Russian).
19. Shvets O.A., Abramov D.S., Khoreva A.L. et al. Rosay–Dorfman – like lymphadenopathy in a patient with Wiskott–Aldrich syndrome: diagnostic difficulties. Pediatric Hematology/Oncology and Immunopathology. 2020; 19 (1): 108–15 (in Russian).
20. Potapenko V.G., Leyenman Ye.Ye., Potikhonova N.A. et al. Fever associated with hardware. Clinical observation. J Infectol. 2019; 12 (3): 126–9. DOI: 10.22625/2072-6732-2019-11-3-126-130 (in Russian).
21. Vaamonde R, Cabrera JM, Vaamonde-Martin RJ et al. Silicone granulomatous lymphadenopathy and siliconomas of the breast. Histol Histopathol 1997; 12: 1003–11.
22. Knösel T, Meisel H, Borgmann A et al. Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol 2005; 58 (8): 872–5. DOI: 10.1136/jcp.2004.022756
23. Sokolovskiy Ye.V., Mikheyev G.N., Rybakova M.G. et al. Sinus histiocytosis of the skin of the face of the nonlangerganic type (cutaneous form of Rosai–Dorfman disease). Vestnik dermatologii i venerologii. 2018; 94 (5): 66–71. DOI: 10.25208/0042-4609-2018-94-5-66-71 (In Russian).
24. Jordan MB, Hult A, Filipovich A. Histiocytic Disorders. In: Hematology: Basic Principles and Practice. Elsevier Inc., 2018.
25. Potekayev N.N., Lvov A.N., Bobko S.I. et al. Cutaneous form of Rosai–Dorfman disease. Rus J Clin Dermatol Venerol. 2017; 16 (1): 30–9. DOI: 10.17116/klinderma201716130-38 (In Russian).
26. Chen HH, Zhou SH, Wang SQ et al. Factors associated with recurrence and therapeutic strategies for sinonasal Rosai–Dorfman disease. Head Neck 2011; 34 (10): 1504–13. DOI: 10.1002/hed.21832
27. Ferry JA, Klepeis V, Sohani AR et al. IgG4-related Orbital Disease and Its Mimics in a Western Population. Am J Surg Pathol 2015; 39 (12): 1688–700. DOI: 10.1097/PAS.0000000000000497
28. Tsang WY, Chan JK, Ho WK et al. Extranodal Rosai–Dorfman disease: an uncommon cause of persistent nodule in the ear. J Laryngol Otol 1992; 106 (3): 249–51. DOI: 10.1017/s0022215100119188
29. Andriko JA, Morrison A, Colegial CH et al. Rosai–Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol 2001; 14 (3): 172–8. DOI: 10.1038/modpathol.3880278
30. Forest F, N'guyen AT, Fesselet J et al. Meningeal Rosai–Dorfman disease mimicking meningioma. Ann Hematol 2014; 93 (6): 937–40. DOI: 10.1007/s00277-013-1994-8
2. Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127 (22): 2672–81. DOI: 10.1182/blood-2016-01-690636
3. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 1990; 7 (1): 19–73.
4. Должанский О.В., Пальцева Е.М., Морозова М.М. и др. Солитарная эпителиоидная гемангиоэндотелиома в сочетании с нодулярным паренхиматозным амилоидозом легкого и болезнью Розаи–Дорфмана. Архив патологии. 2018; 80 (2): 52–9.
[Dolzhanskiy O.V., Pal'tseva Ye.M., Morozova M.M. et al. Solitary epithelioid hemangioendothelioma in combination with nodular parenchymal amyloidosis of the lung and Rosai–Dorfman's disease. Archiv of Patology. 2018; 80 (2): 52–9 (In Russ).]
5. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120 (13): 2700–3.
6. Chakraborty R, Hampton OA, Shen X et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124 (19): 3007–15.
7. Pulsoni A, Anghel G, Falcucci P et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): report of a case and literature review. Am J Hematol 2002; 69 (1): 67–71.
8. Abla O, Jacobsen E, Picarsic J et al. Consensus recommendations for the diagnosis and clinical management of Rosai–Dorfman–Destombes disease. Blood 2018; 131 (26): 2877–90.
9. Меликян А.Л. Синусный гистиоцитоз с массивной лимфаденопатией (болезнь Розаи–Дорфмана). Обзор литературы и случай из практики. Клин. онкогематология. 2008; 1 (3): 252–8.
[Melikyan A.L. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). Literature review and case from practice. Clin Oncohematol. 2008; 1 (3): 252–8 (In Russian).]
10. Sathyanarayanan V, Issa A, Pinto R et al. Rosai–Dorfman disease: the MD Anderson cancer center experience. Clin Lymphoma Myeloma Leuk 2019; 19 (11): 709–14.
11. Al-Khateeb TH. Cutaneous Rosai–Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg. 2016; 74 (3): 528–40.
12. Ян C., Гветадзе Ш.Р., Илькаев К.Д. и др. Экстранодальная интраоссальная болезнь Розаи–Дорфмана в области нижней челюсти: описание клинического случая и обзор литературы. Опухоли головы и шеи. 2018; 8 (2): 34–8. DOI: 10.17650/2222-1468-2018-8-2-34-38
[Yan C., Gvetadze S.R., Il'kayev K.D. et al. Extranodal intraosseous Rozai–Dorfman disease in the mandible: a description of a clinical case and a review of the literature. Head and Nick Tumors. 2018; 8 (2): 34–8. DOI: 10.17650/2222-1468-2018-8-2-34-38 (in Russian).]
13. Goyal G, Ravindran A, Young JR et al. Clinicopathological features, treatment approaches, and outcomes in Rosai–Dorfman disease. Haematologica 2020; 105 (2): 348–57. DOI: 10.3324/haematol.2019.219626
14. Kutlubay Z, Bairamov O, Sevim A et al. Rosai–Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol 2014; 36 (4): 353–7. DOI: 10.1097/DAD.0b013e31829e5564
15. James WD, Berger T, Elston D. Cutaneous lymphoid hyperplasia, cutaneous T-cell lymphoma, other malignant lymphomas, and allied diseases. Andrews' Diseases of the Skin, Clinical Dermatology. 9th ed. Philadelphia: WB Saunders Company, 2019; p. 918–42.
16. Picarsic J, Jaffe R. Pathology of histiocytic neoplasms and related disorders. In: Abla O, Janka G. Histiocytic Disorders. Zurich, Switzerland: Springer International Publishing, 2018; p. 3–50.
17. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 2014; 124 (4): 483–92.
18. Ковригина А.М. Морфологическая характеристика реактивных изменений лимфоузлов. Клин. онкогематология. 2009; 2 (4): 297–305.
[Kovrigina A.M. Morphological characteristics of lymph node reactive changes. Clin Oncohematol. 2009; 2 (4): 297–305 (in Russian).]
19. Швец О.А., Абрамов Д.С., Хорева А.Л. и др. Лимфаденопатия по типу болезни Розаи–Дорфмана у пациента с синдромом Вискотта–Олдрича: сложности диагностики. Вопр. гематологии/онкологии и иммунопатологии в педиатрии. 2020; 19 (1): 108–15.
[Shvets O.A., Abramov D.S., Khoreva A.L. et al. Rosay–Dorfman – like lymphadenopathy in a patient with Wiskott–Aldrich syndrome: diagnostic difficulties. Pediatric Hematology/Oncology and Immunopathology. 2020; 19 (1): 108–15 (in Russian).]
20. Потапенко В.Г., Леенман Е.Е., Потихонова Н.А. и др. Лихорадка, ассоциированная с металлоконструкцией. Клиническое наблюдение. Журн. инфектологии. 2019; 12 (3): 126–9. DOI: 10.22625/2072-6732-2019-11-3-126-130
[Potapenko V.G., Leyenman Ye.Ye., Potikhonova N.A. et al. Fever associated with hardware. Clinical observation. J Infectol. 2019; 12 (3): 126–9. DOI: 10.22625/2072-6732-2019-11-3-126-130 (in Russian).]
21. Vaamonde R, Cabrera JM, Vaamonde-Martin RJ et al. Silicone granulomatous lymphadenopathy and siliconomas of the breast. Histol Histopathol 1997; 12: 1003–11.
22. Knösel T, Meisel H, Borgmann A et al. Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol 2005; 58 (8): 872–5. DOI: 10.1136/jcp.2004.022756
23. Соколовский Е.В., Михеев Г.Н., Рыбакова М.Г. и др. Синусный гистиоцитоз кожи лица нелангергансового типа (кожная форма болезни Розаи–Дорфмана). Вестн. дерматологии и венерологии. 2018; 94 (5): 66–71. DOI: 10.25208/0042-4609-2018-94-5-66-71
[Sokolovskiy Ye.V., Mikheyev G.N., Rybakova M.G. et al. Sinus histiocytosis of the skin of the face of the nonlangerganic type (cutaneous form of Rosai–Dorfman disease). Vestnik dermatologii i venerologii. 2018; 94 (5): 66–71. DOI: 10.25208/0042-4609-2018-94-5-66-71 (In Russian).]
24. Jordan MB, Hult A, Filipovich A. Histiocytic Disorders. In: Hematology: Basic Principles and Practice. Elsevier Inc., 2018.
25. Потекаев Н.Н., Львов А.Н., Бобко С.И. и др. Кожная форма болезни Розаи–Дорфмана. Клин. дерматология и венерология. 2017; 16 (1): 30–9. DOI: 10.17116/klinderma201716130-38
[Potekayev N.N., Lvov A.N., Bobko S.I. et al. Cutaneous form of Rosai–Dorfman disease. Rus J Clin Dermatol Venerol. 2017; 16 (1): 30–9. DOI: 10.17116/klinderma201716130-38 (In Russian).]
26. Chen HH, Zhou SH, Wang SQ et al. Factors associated with recurrence and therapeutic strategies for sinonasal Rosai–Dorfman disease. Head Neck 2011; 34 (10): 1504–13. DOI: 10.1002/hed.21832
27. Ferry JA, Klepeis V, Sohani AR et al. IgG4-related Orbital Disease and Its Mimics in a Western Population. Am J Surg Pathol 2015; 39 (12): 1688–700. DOI: 10.1097/PAS.0000000000000497
28. Tsang WY, Chan JK, Ho WK et al. Extranodal Rosai–Dorfman disease: an uncommon cause of persistent nodule in the ear. J Laryngol Otol 1992; 106 (3): 249–51. DOI: 10.1017/s0022215100119188
29. Andriko JA, Morrison A, Colegial CH et al. Rosai–Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol 2001; 14 (3): 172–8. DOI: 10.1038/modpathol.3880278
30. Forest F, N'guyen AT, Fesselet J et al. Meningeal Rosai–Dorfman disease mimicking meningioma. Ann Hematol 2014; 93 (6): 937–40. DOI: 10.1007/s00277-013-1994-8
________________________________________________
2. Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127 (22): 2672–81. DOI: 10.1182/blood-2016-01-690636
3. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 1990; 7 (1): 19–73.
4. Dolzhanskiy O.V., Pal'tseva Ye.M., Morozova M.M. et al. Solitary epithelioid hemangioendothelioma in combination with nodular parenchymal amyloidosis of the lung and Rosai–Dorfman's disease. Archiv of Patology. 2018; 80 (2): 52–9 (In Russ).
5. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120 (13): 2700–3.
6. Chakraborty R, Hampton OA, Shen X et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 2014; 124 (19): 3007–15.
7. Pulsoni A, Anghel G, Falcucci P et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease): report of a case and literature review. Am J Hematol 2002; 69 (1): 67–71.
8. Abla O, Jacobsen E, Picarsic J et al. Consensus recommendations for the diagnosis and clinical management of Rosai–Dorfman–Destombes disease. Blood 2018; 131 (26): 2877–90.
9. Melikyan A.L. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). Literature review and case from practice. Clin Oncohematol. 2008; 1 (3): 252–8 (In Russian).
10. Sathyanarayanan V, Issa A, Pinto R et al. Rosai–Dorfman disease: the MD Anderson cancer center experience. Clin Lymphoma Myeloma Leuk 2019; 19 (11): 709–14.
11. Al-Khateeb TH. Cutaneous Rosai–Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofac Surg. 2016; 74 (3): 528–40.
12. Yan C., Gvetadze S.R., Il'kayev K.D. et al. Extranodal intraosseous Rozai–Dorfman disease in the mandible: a description of a clinical case and a review of the literature. Head and Nick Tumors. 2018; 8 (2): 34–8. DOI: 10.17650/2222-1468-2018-8-2-34-38 (in Russian).
13. Goyal G, Ravindran A, Young JR et al. Clinicopathological features, treatment approaches, and outcomes in Rosai–Dorfman disease. Haematologica 2020; 105 (2): 348–57. DOI: 10.3324/haematol.2019.219626
14. Kutlubay Z, Bairamov O, Sevim A et al. Rosai–Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol 2014; 36 (4): 353–7. DOI: 10.1097/DAD.0b013e31829e5564
15. James WD, Berger T, Elston D. Cutaneous lymphoid hyperplasia, cutaneous T-cell lymphoma, other malignant lymphomas, and allied diseases. Andrews' Diseases of the Skin, Clinical Dermatology. 9th ed. Philadelphia: WB Saunders Company, 2019; p. 918–42.
16. Picarsic J, Jaffe R. Pathology of histiocytic neoplasms and related disorders. In: Abla O, Janka G. Histiocytic Disorders. Zurich, Switzerland: Springer International Publishing, 2018; p. 3–50.
17. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 2014; 124 (4): 483–92.
18. Kovrigina A.M. Morphological characteristics of lymph node reactive changes. Clin Oncohematol. 2009; 2 (4): 297–305 (in Russian).
19. Shvets O.A., Abramov D.S., Khoreva A.L. et al. Rosay–Dorfman – like lymphadenopathy in a patient with Wiskott–Aldrich syndrome: diagnostic difficulties. Pediatric Hematology/Oncology and Immunopathology. 2020; 19 (1): 108–15 (in Russian).
20. Potapenko V.G., Leyenman Ye.Ye., Potikhonova N.A. et al. Fever associated with hardware. Clinical observation. J Infectol. 2019; 12 (3): 126–9. DOI: 10.22625/2072-6732-2019-11-3-126-130 (in Russian).
21. Vaamonde R, Cabrera JM, Vaamonde-Martin RJ et al. Silicone granulomatous lymphadenopathy and siliconomas of the breast. Histol Histopathol 1997; 12: 1003–11.
22. Knösel T, Meisel H, Borgmann A et al. Parvovirus B19 infection associated with unilateral cervical lymphadenopathy, apoptotic sinus histiocytosis, and prolonged fatigue. J Clin Pathol 2005; 58 (8): 872–5. DOI: 10.1136/jcp.2004.022756
23. Sokolovskiy Ye.V., Mikheyev G.N., Rybakova M.G. et al. Sinus histiocytosis of the skin of the face of the nonlangerganic type (cutaneous form of Rosai–Dorfman disease). Vestnik dermatologii i venerologii. 2018; 94 (5): 66–71. DOI: 10.25208/0042-4609-2018-94-5-66-71 (In Russian).
24. Jordan MB, Hult A, Filipovich A. Histiocytic Disorders. In: Hematology: Basic Principles and Practice. Elsevier Inc., 2018.
25. Potekayev N.N., Lvov A.N., Bobko S.I. et al. Cutaneous form of Rosai–Dorfman disease. Rus J Clin Dermatol Venerol. 2017; 16 (1): 30–9. DOI: 10.17116/klinderma201716130-38 (In Russian).
26. Chen HH, Zhou SH, Wang SQ et al. Factors associated with recurrence and therapeutic strategies for sinonasal Rosai–Dorfman disease. Head Neck 2011; 34 (10): 1504–13. DOI: 10.1002/hed.21832
27. Ferry JA, Klepeis V, Sohani AR et al. IgG4-related Orbital Disease and Its Mimics in a Western Population. Am J Surg Pathol 2015; 39 (12): 1688–700. DOI: 10.1097/PAS.0000000000000497
28. Tsang WY, Chan JK, Ho WK et al. Extranodal Rosai–Dorfman disease: an uncommon cause of persistent nodule in the ear. J Laryngol Otol 1992; 106 (3): 249–51. DOI: 10.1017/s0022215100119188
29. Andriko JA, Morrison A, Colegial CH et al. Rosai–Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol 2001; 14 (3): 172–8. DOI: 10.1038/modpathol.3880278
30. Forest F, N'guyen AT, Fesselet J et al. Meningeal Rosai–Dorfman disease mimicking meningioma. Ann Hematol 2014; 93 (6): 937–40. DOI: 10.1007/s00277-013-1994-8
Авторы
В.Г. Потапенко*1,2, И.Э. Белоусова3, Ю.Н. Виноградова4, К.А. Келехсаева4, А.М. Улитин4, И.О. Смирнова5,6, Я.Г. Петунова5,6, Н.В. Ильин4
1 ГБУЗ «Городская клиническая больница №31», Санкт-Петербург, Россия;
2 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
3 ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова», Санкт-Петербург, Россия;
4 ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» Минздрава России, Санкт-Петербург, Россия;
5 ГБУЗ «Городской кожно-венерологический диспансер», Санкт-Петербург, Россия;
6 ФГБОУ ВО «Санкт-Петербургский государственный университет», Санкт-Петербург, Россия
*potapenko.vsevolod@mail.ru
1 Municipal Clinical Hospital №31, Saint Petersburg, Russia;
2 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
3 Kirov Military Medical Academy, Saint Petersburg, Russia;
4 Granov Russian Research Center for Radiology and Surgical Technologies, Saint Petersburg, Russia;
5 Municipal Hospital of Venerological and Skin Diseases, Saint Petersburg, Russia;
6 Saint Petersburg State University, Saint Petersburg, Russia
*potapenko.vsevolod@mail.ru
1 ГБУЗ «Городская клиническая больница №31», Санкт-Петербург, Россия;
2 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
3 ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова», Санкт-Петербург, Россия;
4 ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» Минздрава России, Санкт-Петербург, Россия;
5 ГБУЗ «Городской кожно-венерологический диспансер», Санкт-Петербург, Россия;
6 ФГБОУ ВО «Санкт-Петербургский государственный университет», Санкт-Петербург, Россия
*potapenko.vsevolod@mail.ru
________________________________________________
1 Municipal Clinical Hospital №31, Saint Petersburg, Russia;
2 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
3 Kirov Military Medical Academy, Saint Petersburg, Russia;
4 Granov Russian Research Center for Radiology and Surgical Technologies, Saint Petersburg, Russia;
5 Municipal Hospital of Venerological and Skin Diseases, Saint Petersburg, Russia;
6 Saint Petersburg State University, Saint Petersburg, Russia
*potapenko.vsevolod@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.